PLC Systems to showcase RenalGuard at 2011 EAPCI annual meeting

May 12 2011

PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, today announced it will demonstrate its innovative new product, RenalGuard®, at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).  More than 11,000 clinicians and medical professionals from around the world are expected to attend this event, which will take place in Paris, France from May 17-20, 2011.

In addition, PLC will hold its second annual international distributor meeting, including a presentation on the recently-announced positive results of the investigator-sponsored REMEDIAL II clinical trial by Dr. Carlo Briguori, MD, PhD, Chief, Laboratory of Interventional Cardiology, Clinica Mediterranea, Naples, Italy, and Co-Director of Clinical Research, Laboratory of Interventional Cardiology, San Raffaele Hospital, Milan, Italy, the principal investigator of the trial. Those results indicated that RenalGuard was more effective than the standard of care in preventing the onset of Contrast-Induced Nephropathy (CIN) in at-risk patients, and that its use also greatly reduced the need for dialysis by those patients, with 4.8 percent of patients in the control group requiring some level of dialysis compared to only 0.7 percent in the RenalGuard-treated group.

Mark R. Tauscher, president and chief executive officer of PLC Systems, said, "CIN is a significant and growing concern worldwide, and we are very encouraged by the prospect that RenalGuard could prevent it. The very positive results from the REMEDIAL II trial in Italy showed that at-risk patients treated with PLC's RenalGuard had a 46% lower incidence of CIN and an 85% lower rate of requiring dialysis, both of which are clinically significant and meaningful in terms of patient care and costs.   EuroPCR, one of the premier international cardiovascular events of the year, is a wonderful opportunity for us to showcase these results with our distributors and medical professionals in Europe."